In line with the results from previous observational studies , vildagliptin was shown in this interventional study to be an effective , safe , and well-tolerated treatment in patients with T2DM fasting during Ramadan , with a consistently low incidence of hypoglycemia across studies , accompanied by good glycemic and weight control .